Sophie Porret

Sophie Porret is responsible for the upstream and downstream development of SpyBiotech’s lead vaccine candidate to combat human cytomegalovirus (CMV) and is overseeing its transfer to pre-clinical process development.

Sophie started her career in industry as a scientist in early-stage research into protein expression and purification at a French start-up company, PX’Therapeutics. Moving to UCB in Brussels, she focused on operational and analytical support for manufacturing biological drugs for human use. She joined SpyBiotech in August 2017 from the UK division of UCB where she specialized in executing process understanding and optimization for drugs approaching Phase III clinical studies.

Sophie received her Master’s Degree in Immunology, Infectious disease and Microbiology from the Joseph Fourier University of Grenoble, France.